Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 3
1957 1
1958 1
1959 2
1960 2
1961 3
1962 1
1963 1
1964 1
1965 3
1966 1
1967 1
1968 1
2015 1
2016 2
2017 6
2018 8
2019 3
2020 4
2021 6
2022 4
2023 5
2024 10
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
Afferi L, Cimadamore A, Gallioli A, Pradere B, Mertens LS, Marcq G, Anguera G, Necchi A, Briganti A, Montorsi F, Rouprêt M, Gontero P, Breda A, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. Afferi L, et al. Among authors: anguera g. Eur Urol. 2025 Jan;87(1):1-4. doi: 10.1016/j.eururo.2024.08.033. Epub 2024 Sep 11. Eur Urol. 2025. PMID: 39266382
What About Variant Histologies in Bladder Cancer?
Day E, Gavira J, Tapia JC, Anguera G, Maroto P. Day E, et al. Among authors: anguera g. Eur Urol Focus. 2024 Mar;10(2):227-230. doi: 10.1016/j.euf.2024.05.015. Epub 2024 Jun 6. Eur Urol Focus. 2024. PMID: 38849276 Review.
Porphycenes and Related Isomers: Synthetic Aspects.
Anguera G, Sánchez-García D. Anguera G, et al. Chem Rev. 2017 Feb 22;117(4):2481-2516. doi: 10.1021/acs.chemrev.6b00345. Epub 2016 Dec 13. Chem Rev. 2017. PMID: 27958722 Review.
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-García LJ, Montero-Conde C, Cascón A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C. Roldán-Romero JM, et al. Among authors: anguera g. Int J Cancer. 2023 Sep 15;153(6):1300-1312. doi: 10.1002/ijc.34575. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260183
66 results